NCT05653011Recruiting
Predictors of Prognosis in IBD Patients
Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 25 Oct 2022
- Start date
- 11 Mar 2013
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Seoul National University Bundang Hospital
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT05653011
What you commit to
- Study type: Observational
- Planned participants: 100
- From 11 Mar 2013 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who were treated with antibiotics or probiotics within the last 3 months
Age
- Age under 18 years
Who the study is looking for
- control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma)
- TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment
- TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.